Harvard Bioscience (HBIO) Depreciation & Amortization (CF) (2010 - 2026)
Harvard Bioscience (HBIO) reported Depreciation & Amortization (CF) of $443000.0 for Q1 2026, down 1.77% year-over-year from $451000.0 in Q1 2025, and up 7.26% quarter-over-quarter from $413000.0 in Q4 2025.
Harvard Bioscience (HBIO) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $443000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $443000.0, down 1.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (down 3.15% YoY), and the FY2025 annual result was $1.7 million, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) rose to $443000.0 in Q1 2026 per HBIO's latest filing, from $413000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $451000.0 in Q1 2025 and troughed at $331000.0 in Q4 2022.
- A 5-year average of $399764.7 and a median of $413000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) fell 29.57% in 2022, then advanced 28.61% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $331000.0 in 2022, then climbed by 25.98% to $417000.0 in 2023, then grew by 3.6% to $432000.0 in 2024, then fell by 4.4% to $413000.0 in 2025, then rose by 7.26% to $443000.0 in 2026.
- Business Quant data shows HBIO's Depreciation & Amortization (CF) at $443000.0 in Q1 2026, $413000.0 in Q4 2025, and $425000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 178.90 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 563.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 254.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 58.98 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 44.60 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 135.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 95.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 56.55 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 237.00 Mn |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | 443,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 443,000.00 |
| Mar 31, 2026 | 443,000.00 |
| Dec 31, 2025 | 413,000.00 |
| Dec 31, 2025 | 413,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | 411,000.00 |
| Jun 30, 2025 | 411,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Dec 31, 2024 | 432,000.00 |
| Dec 31, 2024 | 432,000.00 |
| Sep 30, 2024 | 437,000.00 |
| Sep 30, 2024 | 437,000.00 |
| Jun 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 427,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Dec 31, 2023 | 417,000.00 |
| Dec 31, 2023 | 417,000.00 |